| Literature DB >> 34048764 |
Sue Xue Wang1, M Blair Marshall2.
Abstract
Definitive chemoradiation therapy avoids the perioperative and long-term morbidity of esophagectomy and is the standard of care for cervical esophageal cancer. There are significant differences in tumor response to chemoradiation and recurrence patterns between squamous cell cancer and adenocarcinoma of the esophagus. Multimodality therapy for esophageal cancer continues to progress, now with the widespread use of PET scanning and possible active surveillance in patients with complete clinical response to chemoradiation. As drug development and targeted therapy trials continue to expand, our understanding of tumor biology and precision medicine will continue to refine the treatment of esophageal cancer.Entities:
Keywords: Definitive chemoradiation; Esophageal carcinoma; Immunotherapy; Multimodality therapy
Year: 2021 PMID: 34048764 DOI: 10.1016/j.suc.2021.03.006
Source DB: PubMed Journal: Surg Clin North Am ISSN: 0039-6109 Impact factor: 2.741